【释疑】美国疫苗NVX-CoV2373的技术核心-【蛋白质与多肽药物结构分析网】技术资料

蛋白质与多肽药物结构分析网www.tofms.org

【互联网 www.tofms.org】【My Blog】

如需转载本站内容，请注明资料来源于: www.tofms.org

【技术】【释疑】美国疫苗NVX-CoV2373的技术核心

这两天，川某某又吹了，美国国防部投资疫苗了。这是个什么疫苗呢？本人快速追踪了一下，看下面的描述。

【1】新闻要点

06/04/2020: Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
• $60 million funding for manufacturing of NVX-CoV2373
• 10 million doses to be delivered to U.S. Department of Defense (DoD) in 2020

05/27/2020: Novavax Expands Large-Scale Global Manufacturing Capacity

05/25/2020: Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

The Phase 1 portion is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of NVX CoV2373, both adjuvanted with Matrix M and unadjuvanted. The trial is enrolling approximately 130 healthy participants 18 to 59 years of age at two sites in Australia. The protocol’s two-dose trial regimen assesses two dose sizes (5 and 25 micrograms) with Matrix M and without.

The Phase 2 portion is expected to be conducted in multiple countries, including the United States, and would assess immunity, safety and COVID 19 disease reduction in a broader age range. This Phase 1/2 approach allows for rapid advancement of NVX CoV2373 during the pandemic. The trial is being supported by the recently announced funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI).

Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.

【2】NVX‐CoV2373技术要点（流感病毒载体疫苗）

• a prefusion, stable recombinant SARS‐CoV‐2 Spike protein nanoparticle vaccine
• Seasonal InfluenzaNanoFlu Nanoparticle Vaccine (qNIV)
• Nanoparticle and Matrix M adjuvant share many similarities with NVX‐CoV237
• SARS CoV‐2 Spike (S) gene synthesized by GenScript and delivered Jan 20
• Engineered >20 constructs.
• Screened for hACE2‐binding, stability,productivity, immunogenicity.
• Developed from a gene sequence to phase 1 in ~90 days nanoparticle vaccines against Ebola GP and influenza A/H7N9 HA with Matrix M adjuvant 皂苷（saponin）.

【3】Matrix M adjuvant（saponin皂苷佐剂）

Matrix-M is a saponin-based adjuvant consisting of two populations of individually formed 40 nm sized Matrix particles, each with a different and well-characterized saponin fraction with complementary properties ( Fraction-A and Fraction-C, respectively). Matrix-M, used in this study, consists of 85% Matrix-A and 15% Matrix-C. The Matrix particles are formed by formulating purified saponin from Q. saponaria Molina with cholesterol and phospholipid .

【wkh, 2020-06-07 19:14:58】【责任人 wkh】 [已阅读 1941 次]